Investment analysts at StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Get Rating) in a research note issued on Sunday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.
Agile Therapeutics Stock Performance
Shares of AGRX opened at $0.21 on Friday. The business’s 50-day moving average price is $0.26 and its 200 day moving average price is $0.26. The stock has a market capitalization of $8.53 million, a P/E ratio of -0.01 and a beta of 1.13. Agile Therapeutics has a 1-year low of $0.18 and a 1-year high of $11.40.
Institutional Trading of Agile Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in shares of Agile Therapeutics during the second quarter valued at $108,000. Virtu Financial LLC bought a new position in shares of Agile Therapeutics during the fourth quarter worth about $32,000. BlackRock Inc. boosted its position in Agile Therapeutics by 538.6% during the third quarter. BlackRock Inc. now owns 303,799 shares of the specialty pharmaceutical company’s stock valued at $91,000 after purchasing an additional 256,227 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Agile Therapeutics by 281.3% in the first quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 458,300 shares during the last quarter. 5.70% of the stock is currently owned by institutional investors.
About Agile Therapeutics
Agile Therapeutics, Inc is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
- Get a free copy of the StockNews.com research report on Agile Therapeutics (AGRX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.